Caiyun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Caiyun Chen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Xin Ni
National Clinical Research Center for Geriatric Diseases (J.D., M.L., Y.J., X.N.), Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications - Dewei Guo
Department of Gynecology and Obstetrics, Xiangya Hospital Central South University, Changsha 410000, China
1 shared publication - Jing Long
Department of Gynecology and Obstetrics, Xiangya Hospital Central South University, Changsha 410000, China
1 shared publication - Shu Xiao
Department of Gynecology and Obstetrics, Xiangya Hospital Central South University, Changsha 410000, China
1 shared publication - Weiru Zhang
Department of General Medicine, Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Xian K. Zhang
Division of Rheumatology and Immunology, Department of Medicine Medical University of South Carolina Charleston
1 shared publication
Latest Publications
- 29 September 2026
- Published by Wiley in Arthritis & Rheumatology
Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis Partly Through Interacting With FLI ‐1
Objective: Bromodomain 4 (BRD4) could be a therapeutic target in various diseases. We sought to investigate its role in lupus nephritis (LN) progression and explore whether targeting BRD4 could serve as a therapeutic approach for LN. Methods: BRD4 expression in renal cells was evaluated by immunofluorescence. Inhibition of endothelial BRD4 in mice was conducted by using BRD4 short hairpin RNA adeno‐associated virus (shRNA‐AAV) targeting endothelial cells (ECs). Mouse lupus models were MRL/Lpr mice. Human glomerular ECs (GECs) coupled with RNA sequencing, chromatin immunoprecipitation polymerase chain reaction, and protein‐protein interaction assays were performed to define underlying mechanisms. Results: BRD4 expression was increased in renal ECs in patients with LN and in mouse lupus models. Bromodomain and extraterminal inhibitor NHWD870 treatment greatly improved the features of LN in MRL/Lpr mice as evidenced by reduced lesions, IgG and C3 deposition, immune infiltration, and improved ultrastructural morphology in renal tissues. BRD4 shRNA‐AAV treatment robustly ameliorated the hallmark features of LN in MRL/Lpr mice including proteinuria, histologic and ultrastructural morphology of kidney, and IgG and C3 deposition and immune infiltration in kidney in MRL/Lpr mice. Elevated BRD4 led to changes in many pathways linked to LN and promoted permeability and immune responses in GECs, which were associated with their interaction with FLI‐1. BRD4 shRNA‐AAV treatment attenuated FLI‐1 expression in MRL/Lpr mice. BRD4 and FLI‐1 were colocalized in renal ECs, and FLI‐1 expression was elevated in patients with LN. Conclusion: Elevated BRD4 in ECs is involved in LN pathogenesis, which is partly associated with its interaction with FLI‐1. Targeting endothelial BRD4 could be a therapeutic strategy for LN. image
- 29 September 2026
- Published by Wiley in Arthritis & Rheumatology
Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis Partly Through Interacting With FLI ‐1
Objective: Bromodomain 4 (BRD4) could be a therapeutic target in various diseases. We sought to investigate its role in lupus nephritis (LN) progression and explore whether targeting BRD4 could serve as a therapeutic approach for LN. Methods: BRD4 expression in renal cells was evaluated by immunofluorescence. Inhibition of endothelial BRD4 in mice was conducted by using BRD4 short hairpin RNA adeno‐associated virus (shRNA‐AAV) targeting endothelial cells (ECs). Mouse lupus models were MRL/Lpr mice. Human glomerular ECs (GECs) coupled with RNA sequencing, chromatin immunoprecipitation polymerase chain reaction, and protein‐protein interaction assays were performed to define underlying mechanisms. Results: BRD4 expression was increased in renal ECs in patients with LN and in mouse lupus models. Bromodomain and extraterminal inhibitor NHWD870 treatment greatly improved the features of LN in MRL/Lpr mice as evidenced by reduced lesions, IgG and C3 deposition, immune infiltration, and improved ultrastructural morphology in renal tissues. BRD4 shRNA‐AAV treatment robustly ameliorated the hallmark features of LN in MRL/Lpr mice including proteinuria, histologic and ultrastructural morphology of kidney, and IgG and C3 deposition and immune infiltration in kidney in MRL/Lpr mice. Elevated BRD4 led to changes in many pathways linked to LN and promoted permeability and immune responses in GECs, which were associated with their interaction with FLI‐1. BRD4 shRNA‐AAV treatment attenuated FLI‐1 expression in MRL/Lpr mice. BRD4 and FLI‐1 were colocalized in renal ECs, and FLI‐1 expression was elevated in patients with LN. Conclusion: Elevated BRD4 in ECs is involved in LN pathogenesis, which is partly associated with its interaction with FLI‐1. Targeting endothelial BRD4 could be a therapeutic strategy for LN. image
- Open Access
- 11 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 478
SUMOylation Inhibitor TAK-981 Alleviates Hallmark Features of Preeclampsia Related to High Glucocorticoid Exposure by Inhibiting Placental Oxidative Stress in Rats
SUMOylation may be involved in preeclampsia (PE) progression. We aimed to investigate the roles of SUMOylation in PE and its underlying mechanism using animal and cell models. A rat PE model was established by dexamethasone (DEX) treatment from pregnancy day 7.5–17.5. HTR8 and BeWo trophoblasts were used as cell models. Placental RNA-seq analysis coupled with Western blotting showed upregulated SUMOylation in placentas of DEX-treated rats. SUMOylation inhibitor TAK-981 treatment robustly alleviated PE-like features including reduced blood pressure and improved renal injury, fetal weight, spiral artery remodeling and placental blood flow in DEX-treated rats. DEX increased SUMOylation in HTR8 and BeWo cells. TAK-981 reversed DEX-induced dysfunction in HTR8 and BeWo cells, such as migration, invasion and syncytialization. Mass spectrum analysis of SUMO1 immunoprecipitation coupled with functional validation showed that SUMOylated proteins related to oxidative stress caused by DEX were reversed by TAK-981 in cultured trophoblasts. TAK-981 mitigated placental oxidative stress in DEX-treated rats. GEO database combined with Western blotting showed upregulated SUMOylation in human placentas with PE. Our findings indicate that protein SUMOylation is one of the key events in PE, particularly in that associated with high glucocorticoid exposure. Targeting placental SUMOylation might be a promising therapeutic strategy for PE.
- 11 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 478
Open AccessSUMOylation Inhibitor TAK-981 Alleviates Hallmark Features of Preeclampsia Related to High Glucocorticoid Exposure by Inhibiting Placental Oxidative Stress in Rats
SUMOylation may be involved in preeclampsia (PE) progression. We aimed to investigate the roles of SUMOylation in PE and its underlying mechanism using animal and cell models. A rat PE model was established by dexamethasone (DEX) treatment from pregnancy day 7.5–17.5. HTR8 and BeWo trophoblasts were used as cell models. Placental RNA-seq analysis coupled with Western blotting showed upregulated SUMOylation in placentas of DEX-treated rats. SUMOylation inhibitor TAK-981 treatment robustly alleviated PE-like features including reduced blood pressure and improved renal injury, fetal weight, spiral artery remodeling and placental blood flow in DEX-treated rats. DEX increased SUMOylation in HTR8 and BeWo cells. TAK-981 reversed DEX-induced dysfunction in HTR8 and BeWo cells, such as migration, invasion and syncytialization. Mass spectrum analysis of SUMO1 immunoprecipitation coupled with functional validation showed that SUMOylated proteins related to oxidative stress caused by DEX were reversed by TAK-981 in cultured trophoblasts. TAK-981 mitigated placental oxidative stress in DEX-treated rats. GEO database combined with Western blotting showed upregulated SUMOylation in human placentas with PE. Our findings indicate that protein SUMOylation is one of the key events in PE, particularly in that associated with high glucocorticoid exposure. Targeting placental SUMOylation might be a promising therapeutic strategy for PE.